Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (599)	4/15/1999 1:34:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4974

Agreed, on every point. However, many of us feel that this low morale point is the "go" signal. The volatility in these suckers is extreme right now. One can trade and hold the same issues, and do quite well.

To: RWReeves who wrote (599)	4/15/1999 8:22:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4974

<<can't make a pipeline without 'em but I don't think the value of even pre-clinical tox and phase I is very high relative to the discounted risk adjusted earnings stream potential. There's been too much in the last few years that hits the wall in a big, ugly way in Phase III that makes coming out of this intact what I look for. >> I disagree with your view on how to validate early clinical results as future earning stream and calculate risk/reward ratio. By the some measure successful PIII trials or drug on market do not protect from risk, even when they are discounted, not to mentioned overvalued. There are to many example to start mentioned individually. With a good understanding of the important factor which will determine drug future (and value for some of this factors are from preclinical and pharmacology data) one can with good probability project drug success. I am not saying that I can do this, but I do tried. So, my vote for SU6668 wasn't based solely on early PI news, it was combination of the pass experience and what is around the candidate. I agree that early clinical data aren't drawing force in bt universe, but how efficient is market for bt sector speak for itself. Miljenko